Company Overview of MacroGenics, Inc.
MacroGenics, Inc., a biopharmaceutical company, focuses on discovering and developing antibody-based therapeutics for the treatment of cancer primarily by modulating the human immune system, as well as various autoimmune disorders and infectious diseases. Its advanced clinical product candidate is Margetuximab, a monoclonal antibody that is in Phase III clinical trial, which targets human epidermal growth factor receptor 2-expressing tumors, including certain types of breast and gastroesophageal cancers. The company also develops Enoblituzumab, an antibody that is in Phase 1 clinical trial as monotherapy in multiple dose expansion cohorts; MGD006, a DART molecule that targets CD123 and CD3; ...
9640 Medical Center Drive
Rockville, MD 20850
Founded in 2000
Key Executives for MacroGenics, Inc.
Chief Executive Officer, President and Director
Total Annual Compensation: $523.0K
Chief Financial Officer, Senior Vice President and Corporate Secretary
Total Annual Compensation: $336.5K
Chief Medical Officer and Senior Vice President of Clinical Development
Total Annual Compensation: $380.8K
Senior Vice President and General Counsel
Total Annual Compensation: $357.7K
Chief Scientific Officer and Senior Vice President of Research
Total Annual Compensation: $353.0K
Compensation as of Fiscal Year 2015.
MacroGenics, Inc. Key Developments
MacroGenics Announces Executive Appointments
Jan 25 17
MacroGenics, Inc. appointed Karen J. Ferrante, M.D., and Scott Jackson to fill the newly created vacancies. Dr. Ferrante will serve on the Nominating & Corporate Governance Committee of the Board and Mr. Jackson will serve on the Compensation Committee of the Board. Dr. Ferrante most recently served as Chief Medical Officer and Head of Research and Development at Tokai Pharmaceuticals and brings over 20 years of oncology drug development experience to the Board. Prior to Tokai, Dr. Ferrante held several senior level positions at Millennium Pharmaceuticals and parent company Takeda Pharmaceuticals, including Oncology Therapeutic Area Head, Takeda Cambridge Site Head and Chief Medical Officer. Dr. Ferrante has also previously held positions of increasing responsibility at Pfizer Global Research and Development and Bristol-Myers Squibb. Mr. Jackson served as Chief Executive Officer and as a member of the Board of Directors of Celator Pharmaceuticals, Inc. from April 2008 until July 2016, when the company was acquired by Jazz Pharmaceuticals plc. Mr. Jackson has more than 25 years of experience in the pharmaceutical and biotechnology industry and has held positions of increasing responsibility in sales, marketing and commercial development at Eli Lilly & Co., SmithKline Beecham, ImClone Systems Inc., Centocor Inc.
MacroGenics, Inc. Presents at The Leerink Partners 6th Annual Global Healthcare Conference, Feb-16-2017 09:30 AM
Jan 24 17
MacroGenics, Inc. Presents at The Leerink Partners 6th Annual Global Healthcare Conference, Feb-16-2017 09:30 AM. Venue: Lotte New York Palace, 455 Madison Ave., New York, New York, United States. Speakers: Scott Koenig, Chief Executive Officer, President and Director.
MacroGenics, Inc. Presents at SunTrust Robinson Humphrey 2017 Orphan Drug Day, Feb-14-2017
Jan 19 17
MacroGenics, Inc. Presents at SunTrust Robinson Humphrey 2017 Orphan Drug Day, Feb-14-2017 . Venue: JW Marriott Essex House New York, 160 Central Park South (b/w 58th & 59th Street), New York, NY 10019, United States.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|